CA3040922A1 - Compositions pharmaceutiques et procedes pour le traitement du cancer - Google Patents

Compositions pharmaceutiques et procedes pour le traitement du cancer Download PDF

Info

Publication number
CA3040922A1
CA3040922A1 CA3040922A CA3040922A CA3040922A1 CA 3040922 A1 CA3040922 A1 CA 3040922A1 CA 3040922 A CA3040922 A CA 3040922A CA 3040922 A CA3040922 A CA 3040922A CA 3040922 A1 CA3040922 A1 CA 3040922A1
Authority
CA
Canada
Prior art keywords
methyl
amino
cancer
tyrosine
propanoate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3040922A
Other languages
English (en)
Inventor
Steven Hoffman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tyme Inc
Original Assignee
Tyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/351,966 external-priority patent/US10272068B2/en
Application filed by Tyme Inc filed Critical Tyme Inc
Publication of CA3040922A1 publication Critical patent/CA3040922A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Emergency Medicine (AREA)

Abstract

L'invention concerne des compositions pharmaceutiques et des kits qui comprennent un inhibiteur de tyrosine hydroxylase, de la mélanine, un promoteur de mélanine ou une combinaison de ceux-ci, un promoteur de p450 3A4 et un inhibiteur de leucine aminopeptidase. L'invention concerne également des procédés de traitement du cancer chez un sujet, comprenant l'administration d'une quantité efficace d'un inhibiteur de tyrosine hydroxylase, d'un promoteur de mélanine, d'un promoteur de p450 3A4 et d'un inhibiteur de leucine aminopeptidase au sujet qui en a besoin. L'invention concerne également des procédés de réduction de la prolifération cellulaire chez un sujet, comportant l'administration d'une quantité efficace d'un inhibiteur de tyrosine hydroxylase, d'un promoteur de mélanine, d'un promoteur de p450 3A4 et d'un inhibiteur de leucine aminopeptidase au sujet qui en a besoin.
CA3040922A 2016-11-15 2017-11-15 Compositions pharmaceutiques et procedes pour le traitement du cancer Pending CA3040922A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/351,966 US10272068B2 (en) 2012-01-17 2016-11-15 Pharmaceutical compositions and methods
US15/351,966 2016-11-15
PCT/US2017/061682 WO2018093820A1 (fr) 2016-11-15 2017-11-15 Compositions pharmaceutiques et procédés pour le traitement du cancer

Publications (1)

Publication Number Publication Date
CA3040922A1 true CA3040922A1 (fr) 2018-05-24

Family

ID=60570232

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3040922A Pending CA3040922A1 (fr) 2016-11-15 2017-11-15 Compositions pharmaceutiques et procedes pour le traitement du cancer

Country Status (12)

Country Link
EP (1) EP3541411A1 (fr)
JP (2) JP2019537608A (fr)
KR (2) KR20230003314A (fr)
CN (1) CN110167580A (fr)
AU (1) AU2017361080A1 (fr)
BR (1) BR112019009799A2 (fr)
CA (1) CA3040922A1 (fr)
EA (1) EA201991192A1 (fr)
IL (1) IL266486A (fr)
MX (1) MX2019005450A (fr)
PH (1) PH12019500758A1 (fr)
WO (1) WO2018093820A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020232227A1 (fr) 2019-05-14 2020-11-19 Tyme, Inc. Compositions et méthodes de traitement du cancer
CN114599352A (zh) * 2019-10-15 2022-06-07 迪美公司 用于治疗癌症的α-甲基-DL-酪氨酸烷基酯
IL294803A (en) * 2020-01-17 2022-09-01 Tyme Inc Tyrosine derivatives for modulating cancer
CN111358777A (zh) * 2020-02-24 2020-07-03 军事科学院军事医学研究院环境医学与作业医学研究所 一种提高外周血单个核细胞线粒体功能的方法和应用
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections
CN116783212A (zh) * 2020-12-02 2023-09-19 霍夫曼技术有限责任公司 用于调节非人哺乳动物中的癌症的组合物和方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225435A (en) 1990-05-18 1993-07-06 Yale University Soluble melanin
WO2006032299A1 (fr) * 2004-09-24 2006-03-30 Susanna Miettinen Utilisation d'inhibiteurs de 24-hydroxylase dans le traitement d'un cancer
US20060078494A1 (en) * 2004-09-24 2006-04-13 Sapphire Therapeutics, Inc. Use of inhibitors of 24-hydroxylase in the treatment of cancer
US20130183263A1 (en) * 2012-01-17 2013-07-18 Steven Hoffman Pharmaceutical compositions and methods
PH12014501639B1 (en) * 2012-01-17 2023-02-22 Tyme Inc Pharmaceutical compositions and methods
US8481498B1 (en) * 2012-01-17 2013-07-09 Steven Hoffman Pharmaceutical compositions and methods
US9585841B2 (en) * 2013-10-22 2017-03-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them

Also Published As

Publication number Publication date
WO2018093820A1 (fr) 2018-05-24
JP2023018029A (ja) 2023-02-07
KR20190084291A (ko) 2019-07-16
KR20230003314A (ko) 2023-01-05
EA201991192A1 (ru) 2019-10-31
EP3541411A1 (fr) 2019-09-25
AU2017361080A1 (en) 2019-05-02
JP2019537608A (ja) 2019-12-26
CN110167580A (zh) 2019-08-23
MX2019005450A (es) 2019-07-04
IL266486A (en) 2019-07-31
PH12019500758A1 (en) 2019-07-24
BR112019009799A2 (pt) 2019-08-06

Similar Documents

Publication Publication Date Title
US10307465B2 (en) Pharmaceutical compositions and methods
CA2862689C (fr) .alpha.-methyl-dl-tyrosine, compositions, trousses, combinaisons et utilisation associee destines au traitement du cancer ou a la reduction de la proliferation cellulaire
US11052068B2 (en) Pharmaceutical compositions and methods
CA3040922A1 (fr) Compositions pharmaceutiques et procedes pour le traitement du cancer
US11103559B2 (en) Pharmaceutical compositions and methods
US20210386832A1 (en) Pharmaceutical Compositions And Methods
EA042139B1 (ru) Фармацевтические композиции и способы лечения рака

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20221115